|
Atezolizumab is a fully humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of metastatic non-small cell lung cancer (NSCLC). It binds to the protein programmed cell death-ligand 1 (PD-L1) on several tumors. Atezolizumab has ability to block the binding of PD-L1 with PD-1 and CD80 receptors (B7-1Rs), which has a positive effect on improving an anti-tumor response.
|